There are FDA-approved biologics targeting IL-17A, such as secukinumab, ixekizumab, bimekizumab, and brodalumab (5), raising the possibility that such drugs might find utility in the treatment of chronic CHIKV arthropathy. Here, IL17A is linked to arthropathy.